Terns Pharmaceuticals (TERN) has suddenly landed on many investors radar after reporting encouraging CARDINAL trial data for its CML pill, with major molecular response rates and cancer cell ...
Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...
While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...
This was not the first presentation on STI-571, but it was the one that would change everything: The New England Journal of ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, ...
Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...
In chronic myeloid leukemia, combining asciminib with a tyrosine kinase inhibitor shows increasing efficacy and tolerability over 3 years.
Leukemia and lymphoma are cancers that affect the blood or bone marrow. Fifteen percent of people with leukemia have chronic myeloid leukemia (CML), which has seen a 55% jump in new cases over the ...
Novartis Canada is pleased to announce that Scemblix® (asciminib) is one of the first therapies to be prioritized for public reimbursement under Ontario’s new ...
An advocate discusses vital patient-provider conversations to promote the best care for individuals with chronic myeloid leukemia. Receiving a diagnosis of chronic myeloid leukemia (CML) can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback